CALCIUM CHANNEL BLOCKERS IN BREAST CANCER ETIOLOGY

描述：（改编自申请人摘要）。 虽然超过三分之一的 在65-79岁的妇女中诊断出的所有乳腺癌中， 流行病学研究特别关注女性乳腺癌 在这个年龄。 这个年龄段的女性通常还患有高血压或 冠状动脉疾病和钙通道阻滞剂（CCB）通常用于 治疗这两种情况。 最近有两项研究尚未发表， 65岁及以上的女性，表明使用CCB的女性可能处于 增加乳腺癌的风险。 这种怀疑的联系是 通过观察到药理学阻断的生物学合理性 钙通道可以抑制细胞凋亡（程序性细胞死亡）， 生物体消除不需要的细胞的过程（例如，癌前病变， 启动、损坏、过度）。 从这个意义上说，CCBs可能是癌症 发起人。 该申请建议对1,000名年龄在65-79岁的妇女进行病例对照研究， 居住在华盛顿金县的人，他们是医疗保健融资 管理（HCFA）磁带，谁被诊断为他们的第一个侵入性 在1997年1月1日至12月31日期间的乳腺癌， 1999. 这些女性对吸毒的个人采访反应， 其他已知的乳腺癌危险因素将与对照组进行比较， 一组1,000名没有乳腺癌的妇女，她们将通过 HCFA的录像带 根据初步研究和证据， 在对细胞的体外研究中，假设使用CCB增加了细胞的增殖。 老年妇女患乳腺癌的风险。 该计划是评估是否钙拮抗剂用于治疗 高血压和心血管疾病促使老年妇女患乳腺癌 65-79岁，是否有任何一种钙通道阻滞剂 与乳腺癌的关系比其他类型更密切。 由于没有研究表明 评估目前或过去使用联合雌激素-孕激素治疗的 这个年龄段的一大群妇女，同时使用激素替代疗法， 这些妇女的激素替代疗法（HRT）可能会影响风险的估计 与CCB相关的数据也将收集和分析其他 药物（即，西咪替丁、抗抑郁药、降脂药）， 这个年龄段的女性使用的。

DESCRIPTION: (Adapted from Applicant's Abstract). Although over one-third of all breast cancers are diagnosed among women aged 65-79 years, little epidemiologic research has specifically focussed on breast cancer in women of this age. Women of this age also commonly suffer from hypertension or coronary disease, and calcium channel blockers (CCBs) are often used to treat either of these conditions. Two recent studies, yet to be published, of women aged 65 and older, suggest that women who use CCBs may be at an increased risk of breast cancer. This suspected association is given biological plausibility by the observation that pharmacological blockade of the calcium channels can inhibit apoptosis (programmed cell death), the process whereby organisms eliminate unwanted cells (e.g., preneoplastic, initiated, damaged, excessive). In this sense, CCBs may be cancer promoters. The application proposes a case-control study of 1,000 women, aged 65-79, who reside in King County, Washington, who are on the Health Care Financing Administration (HCFA) tapes, and who are diagnosed with their first invasive breast cancer during the time period of January 1, 1997 through December 31, 1999. The personal interview responses of these women about drug use and other known risk factors for breast cancer will be compared to a control group of 1,000 women without breast cancer who will be identified through the HCFA tapes. Based on the preliminary studies and the evidence from in vitro studies on cells, it is posited that the use of CCBs increases the risk of breast cancer in older women. The plan is to assess whether calcium antagonists used in the treatment of hypertension and cardiovascular diseases promote breast cancer in women aged 65-79 years, and whether any one type of calcium channel blocker is more related to breast cancer than the other types. Since no studies have assessed present or past use of combined estrogen-progestin therapy in a large group of women this age, and the concurrent use of hormone replacement therapy (HRT) by these women may affect the proposed estimates of risk associated with CCBs, data will also be collected and analyzed on other drugs (viz., cimetidine, anti-depressants, lipid lowering drugs) frequently used by women in this age group.